# Epigenetics of Genes Displaying High and Preferential Expression in Myoblasts

**Authors:** Kenneth C. Ehrlich, Michelle Lacey, Sriharsa Pradhan, Melanie Ehrlich

PMC · DOI: 10.3390/epigenomes10010020 · 2026-03-13

## TL;DR

This study explores how DNA methylation patterns in myoblasts influence gene expression, revealing unique epigenetic mechanisms that regulate transcription levels in muscle cells.

## Contribution

The study identifies novel epigenetic roles of DNA hypo- and hypermethylation in modulating transcription levels in myoblasts, beyond traditional on–off regulation.

## Key findings

- Myoblast-associated promoter hypomethylation is prevalent among genes preferentially expressed in myoblasts.
- Hypermethylated DMRs in intragenic regions may repress alternative promoters and downmodulate gene expression in myoblasts.
- Epigenetic insights help explain transcription regulation of genes linked to muscle and heart disorders.

## Abstract

Background/Objectives: Genome-wide studies of differential DNA methylation often focus on its role in turning transcription on or off. Here we report some atypical epigenetic/transcription relationships for 92 genes that are highly and preferentially expressed in primary human myoblasts relative to heterologous cell cultures. Methods: We compared methylomes and myoblast-specific differentially methylated regions (DMRs) with methylomes, chromatin profiles, and transcriptomes for many different cell populations. Results: We found that myoblast-associated promoter hypomethylation was unusually prevalent among the 92 myoblast-preferential genes. Sometimes this promoter hypomethylation was seen as a myoblast-associated extension of their constitutively unmethylated region at a CpG island. All 92 genes showed some myoblast-specific hypomethylation, including 32 genes at tissue-specific super-enhancers or broad H3K4-trimethylated promoters. Myoblast hypermethylated DMRs were also associated with almost half of the myoblast-preferential genes. These hypermethylated DMRs were often in intragenic locations embedded in H3K36-trimethylated chromatin in myoblasts. Conclusions: Our analysis suggests that some of the hypermethylated DMRs repress cryptic, alternative, or adjacent promoters. Myoblast hypermethylated DMRs may also downmodulate expression in myoblasts to avoid yet higher RNA levels found in adult or fetal skeletal muscle tissue. The epigenetic insights that were obtained can help elucidate the transcription regulation of some of these genes (e.g., MUSK, RAPSN, HEYL, SYNPO2, SYNPO2L, STAC3, PITX2, and TPPP3) that are implicated in congenital myasthenic syndromes, myasthenia gravis, muscle repair, heart dysfunction, or cancer. This study supports cell type-specific roles for DNA hypo- and hypermethylation as a modulator of transcription levels, in addition to being an on–off switch during differentiation.

## Linked entities

- **Genes:** MUSK (muscle associated receptor tyrosine kinase) [NCBI Gene 4593], RAPSN (receptor associated protein of the synapse) [NCBI Gene 5913], HEYL (hes related family bHLH transcription factor with YRPW motif like) [NCBI Gene 26508], SYNPO2 (synaptopodin 2) [NCBI Gene 171024], SYNPO2L (synaptopodin 2 like) [NCBI Gene 79933], STAC3 (SH3 and cysteine rich domain 3) [NCBI Gene 246329], PITX2 (paired like homeodomain 2) [NCBI Gene 5308], TPPP3 (tubulin polymerization promoting protein family member 3) [NCBI Gene 51673]
- **Diseases:** congenital myasthenic syndromes (MONDO:0018940), myasthenia gravis (MONDO:0009688), cancer (MONDO:0004992)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** TNNT3 (troponin T3, fast skeletal type) [NCBI Gene 7140] {aka DA2B2, TNTF, beta-TnTF}, SIM2 (SIM bHLH transcription factor 2) [NCBI Gene 6493] {aka HMC13F06, HMC29C01, SIM, bHLHe15}, CDH15 (cadherin 15) [NCBI Gene 1013] {aka CDH14, CDH3, CDHM, MCAD, MRD3}, KCNC1 (potassium voltage-gated channel subfamily C member 1) [NCBI Gene 3746] {aka EPM7, KV3.1, KV4, NGK2}, FNDC5 (fibronectin type III domain containing 5) [NCBI Gene 252995] {aka FRCP2, irisin}, MYH7 (myosin heavy chain 7) [NCBI Gene 4625] {aka CMD1S, CMH1, CMYO7A, CMYO7B, CMYP7A, CMYP7B}, Myod1 (myogenic differentiation 1) [NCBI Gene 17927] {aka MYF3, MyoD, Myod-1, bHLHc1}, HEYL (hes related family bHLH transcription factor with YRPW motif like) [NCBI Gene 26508] {aka HESR3, HEY3, HRT3, bHLHb33}, PITX2 (paired like homeodomain 2) [NCBI Gene 5308] {aka ARP1, ASGD4, Brx1, IDG2, IGDS, IGDS2}, Heyl (hairy/enhancer-of-split related with YRPW motif-like) [NCBI Gene 56198] {aka Hey3, Hrt3, bHLHb33, hesr3}, FOXH1 (forkhead box H1) [NCBI Gene 8928] {aka FAST-1, FAST1}, ZNF556 (zinc finger protein 556) [NCBI Gene 80032], DNAJC5B (DnaJ heat shock protein family (Hsp40) member C5 beta) [NCBI Gene 85479] {aka CSP-beta}, LOC105377363 (uncharacterized LOC105377363) [NCBI Gene 105377363], ADAMTS5 (ADAM metallopeptidase with thrombospondin type 1 motif 5) [NCBI Gene 11096] {aka ADAM-TS 11, ADAM-TS 5, ADAM-TS5, ADAMTS-11, ADAMTS-5, ADAMTS11}, TPPP3 (tubulin polymerization promoting protein family member 3) [NCBI Gene 51673] {aka CGI-38, TPPP/p20, p20, p25gamma}, SYNPO2L (synaptopodin 2 like) [NCBI Gene 79933] {aka CHAP}, TNNC2 (troponin C2, fast skeletal type) [NCBI Gene 7125] {aka CFAP85, CMYO15, CMYP15, FAP85, MYONRI}, ZDHHC1 (zDHHC palmitoyltransferase 1) [NCBI Gene 29800] {aka C16orf1, DHHC-1, HSU90653, ZNF377}, RAPSN (receptor associated protein of the synapse) [NCBI Gene 5913] {aka CMS11, CMS4C, FADS, RAPSYN, RNF205}, CDC73 (cell division cycle 73) [NCBI Gene 79577] {aka C1orf28, FIHP, HPTJT, HRPT1, HRPT2, HYX}, COXFA4L2 (cytochrome c oxidase hypoxia associated subunit FA4L2) [NCBI Gene 56901] {aka MISTRH, NDUFA4L2, NUOMS}, HES1 (hes family bHLH transcription factor 1) [NCBI Gene 3280] {aka HES-1, HHL, HRY, bHLHb39}, TRNG (tRNA-Gly) [NCBI Gene 4563] {aka MTTG}, SYNPO2 (synaptopodin 2) [NCBI Gene 171024], SIX2 (SIX homeobox 2) [NCBI Gene 10736], MYO18B (myosin XVIIIB) [NCBI Gene 84700] {aka KFS4}, SETD2 (SET domain containing 2, histone lysine methyltransferase) [NCBI Gene 29072] {aka HBP231, HIF-1, HIP-1, HSPC069, HYPB, KMT3A}, B3GALT2 (beta-1,3-galactosyltransferase 2) [NCBI Gene 8707] {aka BETA3GALT2, GLCT2, beta3Gal-T2}, CTCF (CCCTC-binding factor) [NCBI Gene 10664] {aka CFAP108, FAP108, MRD21}, SVEP1 (sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1) [NCBI Gene 79987] {aka C9orf13, CCP22, POLYDOM, SEL-OB, SELOB}, TRIM55 (tripartite motif containing 55) [NCBI Gene 84675] {aka MURF-2, RNF29, muRF2}, MYOD1 (myogenic differentiation 1) [NCBI Gene 4654] {aka CMYO17, CMYP17, MYF3, MYOD, MYODRIF, PUM}, DNMT3A (DNA methyltransferase 3 alpha) [NCBI Gene 1788] {aka DNMT3A2, HESJAS, M.HsaIIIA, TBRS}, MYOZ1 (myozenin 1) [NCBI Gene 58529] {aka CS-2, FATZ, MYOZ}, F3 (coagulation factor III, tissue factor) [NCBI Gene 2152] {aka CD142, TF, TFA}, SHMT2 (serine hydroxymethyltransferase 2) [NCBI Gene 6472] {aka GLYA, HEL-S-51e, NEDCASB, SHMT, mSHMT}, DNMT1 (DNA methyltransferase 1) [NCBI Gene 1786] {aka ADCADN, AIM, CXXC9, DNMT, HSN1E, MCMT}, DOK7 (docking protein 7) [NCBI Gene 285489] {aka C4orf25, CMS10, CMS1B}, H3c7 (H3 clustered histone 7) [NCBI Gene 260423] {aka H3.2-221, H3c13, H3c14, H3c15, H3c2, H3c3}, MUSK (muscle associated receptor tyrosine kinase) [NCBI Gene 4593] {aka CMS9, FADS}, CBLL2 (Cbl proto-oncogene like 2) [NCBI Gene 158506] {aka CT138, HAKAIL, ZNF645}, TXN (thioredoxin) [NCBI Gene 7295] {aka TRDX, TRX, TRX1, TXN1, Trx80}, STAC3 (SH3 and cysteine rich domain 3) [NCBI Gene 246329] {aka CMYO13, CMYP13, MYPBB, NAM}, PTGDS (prostaglandin D2 synthase) [NCBI Gene 5730] {aka L-PGDS, LPGDS, PDS, PGD2, PGDS, PGDS2}, DNMT3B (DNA methyltransferase 3 beta) [NCBI Gene 1789] {aka FSHD4, ICF, ICF1, M.HsaIIIB}, IGF2 (insulin like growth factor 2) [NCBI Gene 3481] {aka C11orf43, GRDF, IGF-II, PP9974, SRS3}, ARPP21 (cAMP regulated phosphoprotein 21) [NCBI Gene 10777] {aka ARPP-21, R3HDM3, RCS, TARPP}, CRLF1 (cytokine receptor like factor 1) [NCBI Gene 9244] {aka CISS, CISS1, CLF, CLF-1, NR6, zcytor5}, TBX15 (T-box transcription factor 15) [NCBI Gene 6913] {aka TBX14}
- **Diseases:** sarcopenia (MESH:D055948), congenital myasthenic syndromes (MESH:D020294), heart dysfunction (MESH:D006331), SkM (MESH:D005207), lung cancer (MESH:D008175), injury to (MESH:D014947), congenital muscle disease (MESH:D063806), congenital myopathy (MESH:D009224), cancer (MESH:D009369), myasthenia gravis (MESH:D009157), atrial fibrillation (MESH:D001281), myocardial infarction (MESH:D009203), congenital heart abnormalities (MESH:D006330)
- **Chemicals:** calcium (MESH:D002118), Na-channel blockers (-), 5-hydroxymethylcytosine (MESH:C011865)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** GM12878 — Homo sapiens (Human), Transformed cell line (CVCL_7526), IMR90 — Homo sapiens (Human), Finite cell line (CVCL_0347), SkM — Homo sapiens (Human), Transformed cell line (CVCL_VG48), C2C12 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0188), HMEC — Homo sapiens (Human), Transformed cell line (CVCL_Y905), PrEC — Homo sapiens (Human), Finite cell line (CVCL_0061), ESC — Homo sapiens (Human), Embryonic stem cell (CVCL_9771), foreskin fibroblasts — Homo sapiens (Human), Finite cell line (CVCL_VS58), HUVEC — Homo sapiens (Human), Finite cell line (CVCL_2959), S2 — Drosophila melanogaster (Fruit fly), Spontaneously immortalized cell line (CVCL_Z232), NHEK — Homo sapiens (Human), Finite cell line (CVCL_9Q50)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13025873/full.md

---
Source: https://tomesphere.com/paper/PMC13025873